SUVRETTA CAPITAL MANAGEMENT, LLC
SUVRETTA CAPITAL MANAGEMENT, LLC's purchase track record
How the stock did after each of SUVRETTA CAPITAL MANAGEMENT, LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/4/2026 | MANE | $10.54M | +190.8% | +194.9% | +12.2% |
| 12/26/2025 | BNTC | $1.26M | -21.6% | -5.6% | +6.1% |
| 12/18/2025 | BNTC | $1.18M | +1.1% | +6.8% | +10.7% |
| 11/7/2025 | BNTC | $20.00M | -5.2% | -4.0% | +10.0% |
| 3/26/2025 | BNTC | $11.91M | -6.1% | +0.6% | +16.2% |
| 12/23/2024 | BNTC | $527K | +27.6% | +29.6% | +0.9% |
| 12/3/2024 | BNTC | $403K | +19.7% | +56.1% | -1.3% |
| 11/19/2024 | BNTC | $417K | +14.0% | +41.0% | +0.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Benitec Biopharma shares fell 23.9% over four weeks. Benitec Biopharma's stock dropped 23.9% over the past four weeks, according to a recent Yahoo article. The piece outlines factors that could help the price recover, noting the low RSI of 26.9 and the stock's proximity to a well‑tested support level at $10.89. The company’s average analyst target is $24.33, well above its current range.
Transaction History
| MANE | ▼ Sell | Other | 151,000 | — | 8/20/2026 | View on chart |
| MANE | ▼ Sell | Other | 149,000 | — | 8/20/2026 | View on chart |
| MANE | ▼ Sell | Open Market | 59,399 | $6.4M | 8/19/2026 | View on chart |
| MANE | ▼ Sell | Open Market | 690,601 | $74.1M | 8/19/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 11,183 | $402K | 2/6/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 19,338 | $707K | 2/6/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 3,832 | $138K | 2/5/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 19,199 | $709K | 2/5/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 38,771 | $1.5M | 2/5/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 17,835 | $690K | 2/5/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 16,563 | $659K | 2/5/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 18,489 | $719K | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 53,344 | $2.0M | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 25,908 | $987K | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 1,720 | $59K | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 1,835 | $64K | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 2,519 | $91K | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 9,168 | $340K | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 4,453 | $170K | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 3,178 | $124K | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 10,004 | $343K | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 10,676 | $371K | 2/4/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 14,659 | $532K | 2/4/2026 | View on chart |
| BNTC | ▲ Buy | Open Market | 65,800 | $884K | 12/29/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 11,587 | $156K | 12/29/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 2,516 | $33K | 12/26/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 14,320 | $188K | 12/26/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 42,600 | $547K | 12/23/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 7,400 | $95K | 12/23/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 16,650 | $201K | 12/22/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 2,892 | $35K | 12/22/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 13,950 | $160K | 12/19/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 2,434 | $28K | 12/19/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 8,700 | $98K | 12/18/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 1,515 | $17K | 12/18/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 730,370 | $9.9M | 11/7/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 751,111 | $10.1M | 11/7/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 9,503 | $120K | 3/31/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 1,267 | $16K | 3/31/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 5,057 | $67K | 3/31/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 670 | $9K | 3/31/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 793,800 | $10.3M | 3/26/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 106,200 | $1.4M | 3/26/2025 | View on chart |
| BNTC | ▲ Buy | Open Market | 17,730 | $199K | 12/24/2024 | View on chart |
| BNTC | ▲ Buy | Open Market | 2,288 | $26K | 12/24/2024 | View on chart |
| BNTC | ▲ Buy | Open Market | 24,360 | $267K | 12/23/2024 | View on chart |
| BNTC | ▲ Buy | Open Market | 3,142 | $34K | 12/23/2024 | View on chart |
| BNTC | ▲ Buy | Open Market | 37,190 | $357K | 12/3/2024 | View on chart |
| BNTC | ▲ Buy | Open Market | 4,810 | $46K | 12/3/2024 | View on chart |
| BNTC | ▲ Buy | Open Market | 24,360 | $249K | 11/20/2024 | View on chart |
| BNTC | ▲ Buy | Open Market | 3,076 | $31K | 11/20/2024 | View on chart |
| BNTC | ▲ Buy | Open Market | 12,430 | $121K | 11/19/2024 | View on chart |
| BNTC | ▲ Buy | Open Market | 1,570 | $15K | 11/19/2024 | View on chart |
| BNTC | ▼ Sell | Other | 588,236 | $1.1M | 9/26/2024 | View on chart |
| BNTC | ▼ Sell | Other | 4,605,000 | $17.8M | 9/26/2024 | View on chart |
| BNTC | ▼ Sell | Other | 1,219,970 | $122 | 9/26/2024 | View on chart |
| BNTC | ▼ Sell | Other | 576,347 | $2.2M | 9/26/2024 | View on chart |
| BNTC | ▼ Sell | Other | 148,210 | $15 | 9/26/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Veradermics Momentum Builds, But H2 2026 Readouts Caution
Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.
Veradermics Momentum Builds, But H2 2026 Readouts Caution. Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.